PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.47%
R&D change of 20.47% while RVPH maintains spending. Bruce Berkowitz would investigate effectiveness.
-32.93%
G&A reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-386.54%
Other expenses reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine efficiency.
2.68%
Operating expenses change of 2.68% while RVPH maintains costs. Bruce Berkowitz would investigate control.
2.68%
Total costs growth less than half of RVPH's 3299.79%. David Dodd would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
-4.72%
D&A reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine efficiency.
-2.70%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-2.68%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-10.91%
Other expenses reduction while RVPH shows 1610.56% growth. Joel Greenblatt would examine advantage.
-2.79%
Pre-tax income decline while RVPH shows 1388.22% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.79%
Net income decline while RVPH shows 1388.22% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
1.20%
EPS growth below 50% of RVPH's 726.45%. Michael Burry would check for structural issues.
2.99%
Diluted EPS growth below 50% of RVPH's 726.45%. Michael Burry would check for structural issues.
3.80%
Share count reduction exceeding 1.5x RVPH's 77.74%. David Dodd would verify capital allocation.
6.10%
Diluted share reduction exceeding 1.5x RVPH's 77.74%. David Dodd would verify capital allocation.